Karen A Holbrook Net Worth

The estimated Net Worth of Karen A Holbrook is at least $395 Tausend dollars as of 6 September 2017. Karen Holbrook owns over 1,059 units of Bio-Techne Corp stock worth over $67,170 and over the last 18 years Karen sold TECH stock worth over $328,042.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Karen Holbrook TECH stock SEC Form 4 insiders trading

Karen has made over 6 trades of the Bio-Techne Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently Karen sold 1,059 units of TECH stock worth $128,912 on 6 September 2017.

The largest trade Karen's ever made was exercising 5,000 units of Bio-Techne Corp stock on 25 May 2017 worth over $332,950. On average, Karen trades about 1,062 units every 75 days since 2007. As of 6 September 2017 Karen still owns at least 914 units of Bio-Techne Corp stock.

You can see the complete history of Karen Holbrook stock trades at the bottom of the page.

What's Karen Holbrook's mailing address?

Karen's mailing address filed with the SEC is , , , , .

Insiders trading at Bio-Techne Corp

Over the last 22 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey und John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.

What does Bio-Techne Corp do?

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Complete history of Karen Holbrook stock trades at Bio-Techne Corp

Bio-Techne Corp executives and stock owners

Bio-Techne Corp executives and other stock owners filed with the SEC include:

• Charles Kummeth,
  President, Chief Executive Officer, Director
• Charles R. Kummeth,
  CEO, Pres & Director
• James Hippel,
  Chief Financial Officer, Executive Vice President - Finance
• David Eansor,
  President - Protein Sciences
• Kim Kelderman,
  President - Diagnostics and Genomics
• Brenda Furlow,
  Senior Vice President, General Counsel, Corporate Secretary
• James T. Hippel,
  Exec. VP of Fin. & CFO
• Norman David Eansor,
  Pres of Protein Sciences Segment
• Kim Kelderman,
  Pres of Diagnostics & Genomics
• Brenda S. Furlow J.D.,
  Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Robert Baumgartner,
  Independent Chairman of the Board
• Rupert Vessey,
  Independent Director
• John Higgins,
  Independent Director
• Randolph Steer,
  Independent Director
• Roeland Nusse,
  Independent Director
• Alpna Seth,
  Independent Director
• Joseph Keegan,
  Independent Director
• David Clair,
  IR Contact Officer
• Julie Bushman,
  Independent Director
• Kevin Smyth,
  Sr. VP & Chief Digital Officer
• Luca Cicchetti,
  Managing Director
• Brenda Everson,
  Sr. VP of HR
• Kevin S. Gould,
  Sr. VP of Diagnostics Reagents Division
• Struan Robertson,
  VP of HR
• Robert M. Gavin,
  VP of Corp. Devel.
• Gerry Andros,
  VP of Sales and Marketing
• Karen A Holbrook,
  Director
• Roger C Lucas,
  
• Charles A Dinarello,
  
• J. Fernando Bazan,
  Chief Technical Officer
• Robert M. Gavin,
  Sen. VP Protein Platforms
• Kevin S Gould,
  SVP Clinical Controls
• Kevin J Reagan,
  Senior VP Biotech
• Gregory J Melsen,
  VP Finance and CFO
• Thomas E Oland,
  President
• Howard V Oconnell,
  Director
• Marcel Veronneau,
  Vice Pres-Hematology Oper.
• James A Weatherbee,
  Chief Scientific Officers
• Monica Tsang,
  Vice President of Research
• Christopher S Henney,
  Director
• G A Herbert,
  Director
• Harold J Wiens,
  
• William Geist,
  PRESIDENT, PROTEIN SCIENCES
• Shane Bohnen,
  SVP - General Counsel
• Matthew Mc Manus,
  President - DGS
• Judith V Klimovsky,
  Director